首页> 外文OA文献 >Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups

【2h】

Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups

机译：对于年龄在46至60岁之间的成人急性髓性白血病，强化巩固治疗与标准巩固和维持治疗相比：欧洲癌症研究与治疗组织（EORTC）的随机III期研究（AML 8B）和Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto（GIMEMA）白血病合作小组

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: Final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups [J] . HengeveldM., SuciuS., KarraschM., Annals of hematology . 2012,第6期

机译：对于年龄在46至60岁之间的成人急性髓性白血病，强化巩固治疗与标准巩固和维持治疗相比：欧洲癌症研究与治疗组织（EORTC）的随机III期研究（AML 8B）和Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto（GIMEMA）白血病合作小组
2. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups [J] . Marysia Hengeveld, Stefan Suciu, Matthias Karrasch, Annals of Hematology . 2012,第6期

机译：对于年龄在46至60岁之间的成人急性髓性白血病，强化巩固治疗与标准巩固和维持治疗相比：欧洲癌症研究与治疗组织（EORTC）的随机III期研究（AML 8B）和Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto（GIMEMA）白血病合作小组
3. Gemtuzumab ozogamicin (Mylotarg|[reg]|) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups [J] . S Amadori, S Suciu, R Stasi, Leukemia . 2005,第10期

机译：Gemtuzumab ozogamicin（Mylotarg | [reg] |）作为单药治疗61岁及以上的急性髓性白血病的体弱患者：AML-15B的最终结果，欧洲癌症研究与治疗组织的第二阶段研究和Gruppo Italiano Malattie Ematologiche dell'Adulto白血病团体
4. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups [O] . Marysia Hengeveld, Stefan Suciu, Matthias Karrasch, -1

机译：对于年龄在46至60岁之间的成人急性髓性白血病强化巩固治疗与标准巩固和维持治疗相比：欧洲癌症研究与治疗组织（EORTC）的随机III期研究（AML 8B）和Gruppo Italiano Malattie Ematologiche Maligne dellAdulto（GIMEMA）白血病合作小组
5. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. [O] . M. Hengeveld, S. Suciu, M. Karrasch, 2012

机译：对于年龄在46至60岁之间的成人急性髓性白血病，强化巩固治疗与标准巩固和维持治疗相比：欧洲癌症研究与治疗组织（EORTC）的随机III期研究（AML 8B）和Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto（GIMEMA）白血病合作小组。

著录项

引文网络

相似文献

相关主题

期刊订阅